TP53 and neoplasm: Mechanistically, YY1 activates oncogenic pathways, such as c-Myc and human epidermal growth factor receptor 2 (HER2), while suppressing those of tumor suppressors, including p53 as well as phosphatase and tensin homolog (PTEN), thereby promoting the cancer process.